TRAW (Traws Pharma) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


TRAW Traws Pharma Inc TRAW
49 GF Score
Price $0.84
GF Value $12.92
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Traws Pharma ROE % Adjusted to Book Value?

Traws Pharma TRAW -0.60% 49 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates TRAW with a GF Score™ of 49/100 and a GF Value™ of $12.92 (Possible Value Trap). The stock has 4 warning signs investors should review.

Traws Pharma's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Traws Pharma's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Traws Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Traws Pharma ROE % Adjusted to Book Value Related Terms

Traws Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Traws Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma ROE % Adjusted to Book Value Chart

Traws Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.28 -106.17 -66.14 0.00 Negative Equity

Traws Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Equity -40.42 -85.34 0.00 0.00

TRAW vs CVM, CRIS, QNCX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Traws Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Traws Pharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Traws Pharma's ROE % Adjusted to Book Value falls into.


TRAW
49GF Score
Traws Pharma Inc TRAW
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Traws Pharma ROE % Adjusted to Book Value Calculation

Traws Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

Traws Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Traws Pharma (TRAW) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Traws Pharma and its competitors.
Is Traws Pharma's ROE % Adjusted to Book Value too high?
Traws Pharma's current ROE % Adjusted to Book Value is 0.00%. Overall, Traws Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Traws Pharma's ROE % Adjusted to Book Value compare to CVM and CRIS?
Traws Pharma's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Traws Pharma and its competitors. Traws Pharma's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traws Pharma stock overvalued right now?
Based on GuruFocus' analysis, Traws Pharma (TRAW) is currently considered Possible Value Trap. The stock's GF Value™ is $12.92, compared to a current price of $0.84 — trading 93.5% below its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. Traws Pharma's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Traws Pharma (TRAW), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Traws Pharma (TRAW) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of $0.84 is trading 93.5% below its estimated GF Value™ of $12.92. GuruFocus considers Traws Pharma to be Possible Value Trap.

Key valuation signals for TRAW:

  • ROE % Adjusted to Book Value: 0.00%
  • GF Value™: $12.92 vs. price of $0.84 (93.5% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Traws Pharma Business Description

Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
49GF Score

Get the complete analysis for TRAW

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.84
Price
$12.92
GF Value